Idelalisib + Bendamustine + Rituximab for Previously Treated iNHL

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma

• IRAS ID

  120841

• Contact name

  Andrew J Davies

• Contact email

  a.davies@southampton.ac.uk

• Sponsor organisation

  Gilead Sciences Inc

• Eudract number

  2012-004034-42

• Clinicaltrials.gov Identifier

  NCT01732926

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0259

• Date of REC Opinion

  18 Jul 2013

• REC opinion

  Further Information Favourable Opinion